Protara Therapeutics (STU:1KPA) Total Liabilities : €8.95 Mil (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Protara Therapeutics Total Liabilities?

Protara Therapeutics's Total Liabilities for the quarter that ended in Mar. 2024 was €8.95 Mil.

Protara Therapeutics's quarterly Total Liabilities declined from Sep. 2023 (€10.79 Mil) to Dec. 2023 (€9.75 Mil) and declined from Dec. 2023 (€9.75 Mil) to Mar. 2024 (€8.95 Mil).

Protara Therapeutics's annual Total Liabilities increased from Dec. 2021 (€9.45 Mil) to Dec. 2022 (€10.58 Mil) but then declined from Dec. 2022 (€10.58 Mil) to Dec. 2023 (€9.75 Mil).

Protara Therapeutics Total Liabilities Historical Data

The historical data trend for Protara Therapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Protara Therapeutics Total Liabilities Chart

Protara Therapeutics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

3.02

3.22

9.45

10.58

9.75

Protara Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															10.87	9.15	10.79	9.75	8.95

Protara Therapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Protara Therapeutics's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	5.639	+	(4.112	+	-0.0010000000000003
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	9.75

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	72.401	-	62.65
	=	9.75

Protara Therapeutics's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	5.061	+	(3.889	+	-4.4408920985006E-16
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	8.95

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	62.683	-	53.734
	=	8.95

Protara Therapeutics Total Liabilities Related Terms

Thank you for viewing the detailed overview of Protara Therapeutics's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Protara Therapeutics (STU:1KPA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Protara Therapeutics Inc (STU:1KPA) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

TARA:USA 1KPA:Germany

Address

345 Park Avenue South, 3rd Floor, New York, NY, USA, 10010

Website

http://www.protaratx.com

Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with rare and specialty diseases. The company discovers, develops, and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).

Protara Therapeutics (STU:1KPA) Headlines

No Headlines